Mayuko Tsuda1, Yoji Takano, Chika Shigeyasu, Shigeru Imoto, Masakazu Yamada. 1. *Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan; †Department of Ophthalmology, Kawasaki Municipal Ida Hospital, Kawasaki, Japan; and ‡Department of Breast Surgery, Kyorin University School of Medicine, Mitaka, Japan.
Abstract
PURPOSE: To report a case of atypical corneal lesions presumably induced by trastuzumab emtansine, an antibody-drug conjugate that is designed to selectively deliver cytotoxic agents to human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells. CASE: A 64-year-old Japanese woman developed bilateral corneal epithelial abnormalities that originated from the limbus. The corneal lesions covered the superior area in the right eye and both superior and inferior areas including the visual axis in the left eye. The patient had advanced ductal carcinoma of the left breast and had been receiving anticancer treatment with trastuzumab emtansine for 15 months. After switching the chemotherapy from trastuzumab emtansine monotherapy to the combination of docetaxel, trastuzumab, and pertuzumab, the abnormal corneal lesions showed gradual improvement. CONCLUSIONS: As corneal epithelial cells express human epidermal growth factor receptor 2 under normal conditions, such cells may also be targeted by trastuzumab emtansine and lead to corneal epithelial lesions.
PURPOSE: To report a case of atypical corneal lesions presumably induced by trastuzumab emtansine, an antibody-drug conjugate that is designed to selectively deliver cytotoxic agents to humanepidermal growth factor receptor 2 (HER2)-positive breast cancer cells. CASE: A 64-year-old Japanese woman developed bilateral corneal epithelial abnormalities that originated from the limbus. The corneal lesions covered the superior area in the right eye and both superior and inferior areas including the visual axis in the left eye. The patient had advanced ductal carcinoma of the left breast and had been receiving anticancer treatment with trastuzumab emtansine for 15 months. After switching the chemotherapy from trastuzumab emtansine monotherapy to the combination of docetaxel, trastuzumab, and pertuzumab, the abnormal corneal lesions showed gradual improvement. CONCLUSIONS: As corneal epithelial cells express humanepidermal growth factor receptor 2 under normal conditions, such cells may also be targeted by trastuzumab emtansine and lead to corneal epithelial lesions.
Authors: Julia Canestraro; Malin Hultcrantz; Shanu Modi; Paul A Hamlin; Alexander N Shoushtari; Jason A Konner; William P Tew; Neil M Iyengar; Murk Heinemann; David H Abramson; Jasmine H Francis Journal: Cornea Date: 2021-11-23 Impact factor: 3.152
Authors: Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby Journal: Ophthalmol Ther Date: 2020-07-25
Authors: Helio V Neves da Silva; John Placide; Anne Duong; Yasmyne Ronquillo; Shannon McCabe; Majid Moshirfar Journal: Ther Adv Ophthalmol Date: 2022-04-26
Authors: Katharina A Sterenczak; Nadine Stache; Sebastian Bohn; Stephan Allgeier; Bernd Köhler; Andreas Bartschat; Christian George; Rudolf F Guthoff; Oliver Stachs; Angrit Stachs Journal: Diagnostics (Basel) Date: 2021-05-07
Authors: Chen Hong-Jhe; Kuo Chin-Yuan; Tu Ming-Shium; Wang Fu-Wei; Chen Ru-Yih; Hsueh Kuang-Chieh; Pan Hsiang-Ju; Chou Ming-Yueh; Chen Pan-Ming; Pan Chih-Chuan Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889